Humana (NYSE:HUM) Price Target Raised to $290.00 at Truist Financial

Humana (NYSE:HUM) had its target price boosted by equities research analysts at Truist Financial from $260.00 to $290.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the insurance provider’s stock. Truist Financial’s target price would indicate a potential upside of 10.49% from the stock’s previous close.

A number of other equities research analysts also recently commented on the company. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and decreased their price target for the company from $519.00 to $253.00 in a research report on Monday, October 7th. UBS Group cut their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, October 4th. Leerink Partnrs cut shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 target price on shares of Humana in a research report on Tuesday, October 1st. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana currently has a consensus rating of “Hold” and a consensus target price of $302.00.

Humana Trading Up 3.9 %

Shares of Humana stock opened at $262.47 on Monday. The business has a fifty day simple moving average of $272.60 and a 200-day simple moving average of $313.45. The firm has a market cap of $31.60 billion, a price-to-earnings ratio of 23.25, a price-to-earnings-growth ratio of 2.12 and a beta of 0.55. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $471.37. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, equities analysts forecast that Humana will post 16.14 EPS for the current fiscal year.

Insider Buying and Selling at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Institutional Trading of Humana

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Private Advisor Group LLC increased its stake in Humana by 45.3% during the second quarter. Private Advisor Group LLC now owns 2,966 shares of the insurance provider’s stock valued at $1,108,000 after acquiring an additional 925 shares during the period. Candriam S.C.A. raised its stake in shares of Humana by 4.3% in the second quarter. Candriam S.C.A. now owns 8,739 shares of the insurance provider’s stock valued at $3,265,000 after purchasing an additional 359 shares in the last quarter. Lake Street Advisors Group LLC lifted its position in Humana by 32.4% in the second quarter. Lake Street Advisors Group LLC now owns 1,488 shares of the insurance provider’s stock worth $557,000 after purchasing an additional 364 shares during the period. Caprock Group LLC boosted its stake in Humana by 102.7% during the second quarter. Caprock Group LLC now owns 2,722 shares of the insurance provider’s stock worth $1,020,000 after buying an additional 1,379 shares in the last quarter. Finally, Ballentine Partners LLC increased its holdings in Humana by 349.6% in the 2nd quarter. Ballentine Partners LLC now owns 6,335 shares of the insurance provider’s stock valued at $2,367,000 after buying an additional 4,926 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.